AKUMS DRUGS AND PHARMA L is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY25 | FY26 |
|---|---|---|
| Revenue | 4,118 | 4,359 |
| EBITDA (ex other income) | 481 | 502 |
| margin % | 11.7 | 11.5 |
| Owners' profit | 338 | 255 |
| EPS, as reported (₹) | 22.60 | 16.67 |
| ROE % · ROCE % | 11.2 · 11.8 | 7.7 · 10.9 |
| Debt / equity (x) | 0.00 | 0.02 |
| Cash from operations | 465 | 1,181 |
| Capex | (272) | (231) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 |
| Profit before tax | 92 | 91 | 75 | 96 | 66 | 100 | 121 | 139 |
| Net profit | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 |
| EPS (₹) | 4.37 | 4.26 | 9.64 | 4.15 | 2.66 | 4.33 | 5.53 | 6.53 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| CDMO | 3,485 | 80.0 |
| API | 184 | 4.2 |
| Domestic Branded Formulations | 210 | 4.8 |
| International Branded Formulations | 71 | 1.6 |
| Trade Generics | 50 | 1.2 |
| Domestic branded formulations | 237 | 5.4 |
| International branded formulations | 73 | 1.7 |
| Trade generics | 49 | 1.1 |
| Total, before eliminations | 4,359 | 100.0 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 3 Sept 2026 · Akums Drugs receives ESG rating of 65 from NSE Sustainability | business updates | medium | — | — |
| 25 Aug 2026 · Akums Drugs to attend Elara India Dialogue 2026 investor meet | board shareholder meetings | low | — | — |
| 24 Aug 2026 · Akums Drugs cancels Aug 25 Investor Meet due to medical reasons | board shareholder meetings | low | — | — |
| 13 Aug 2026 · Akums Drugs to attend Antique Healthcare Investor Conference on Aug 25 | board shareholder meetings | low | — | — |
| 13 Aug 2026 · Q1 FY27 Earnings Call: Revenue Up 14%, EBITDA Up 35%, Confident on FY27 | investor communications | medium | — | — |
| 10 Aug 2026 · Akums Drugs to attend Emkay Confluence 2026 investor meet on Aug 14 | board shareholder meetings | low | — | — |
| 10 Aug 2026 · Audio recording link shared for Q1 FY27 analysts call | investor communications | low | — | — |
| 10 Aug 2026 · Newspaper Publication of Q1 FY27 Financial Results | compliance | minimal | — | — |
| 10 Aug 2026 · IPO proceeds fully utilized, CRISIL monitoring report for Q1 FY27 | compliance | minimal | — | — |
| 8 Aug 2026 · Akums Q1 FY27 Investor Presentation: Revenue Up 14%, PAT Up 56% | investor communications | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 40.7 | 28.9 | 112 of 169 | 34% |
| P/B | 3.6 | 3.3 | 91 of 163 | 44% |
| ROCE | 8.8 | 10.8 | 108 of 183 | 41% |
| ROE | 7.7 | 10.4 | 103 of 171 | 40% |
| Debt / Equity | 0.0 | 0.1 | 58 of 171 | 67% |
| EBITDA margin | 17.6 | 17.5 | 82 of 165 | 51% |
| Revenue growth | 13.9 | 16.3 | 84 of 161 | 48% |
| Profit growth | 56.1 | 30.9 | 60 of 158 | 62% |
| Market cap | 11864 | 839 | 41 of 182 | 78% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
